// App-Quantinova.ai

TPS357 : A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.

Researchers

Presenter

  • Thomas Enzler

Principal Investigators

  • Neehar Parikh

  • Chih-Yi Liao

  • Aparna Kalyan

  • David Hsieh

  • Kent A. Griffith

  • Vaibhav Sahai

Medical Centers

  • University of Michigan Medical School, Ann Arbor, MI

  • The University of Chicago Medicine, Department of Medicine, Chicago, IL

  • Northwestern University, Chicago, IL

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • University of Michigan, Ann Arbor, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Cirrhosis

  • Solid malignancies

Biomarkers

  • AXL receptor tyrosine kinase

  • Vascular endothelial growth factor A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved